Skip to content

HIsTological and CLinical effects of Imipramine in the treatment of patients with cancer over-expressing Fascin1. (HITCLIF)

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-504943-15-00
Acronym
IMIB-HTF-2021-01
Enrollment
180
Registered
2023-08-07
Start date
2022-08-19
Completion date
Unknown
Last updated
2025-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

and breast cancer)over-expressing Fascin1, Cancer(colon cancer stage II-III, rectal cancer

Brief summary

Changes in the invading front associated with the epithelial-mesenchymal transition quantified as measurement of tumor budding, cytoplasmic pseudofragments, pattern of tumor invasion, and characteristics of the immune infiltrate (intra- and peritumoral lymphocytes, characterization of Crohn-like response macrophages).

Detailed description

Evaluation of plasma quantification of tumor DNA copies and the expression of serum and tissue fascina1 in the surgical resection piece.

Interventions

DRUGSucrose c.s. and lactose c.s.
DRUGTOFRANIL 50 mg comprimidos recubiertos

Sponsors

Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Changes in the invading front associated with the epithelial-mesenchymal transition quantified as measurement of tumor budding, cytoplasmic pseudofragments, pattern of tumor invasion, and characteristics of the immune infiltrate (intra- and peritumoral lymphocytes, characterization of Crohn-like response macrophages).

Secondary

MeasureTime frame
Evaluation of plasma quantification of tumor DNA copies and the expression of serum and tissue fascina1 in the surgical resection piece.

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026